Meeting
2011 ASCO Annual Meeting
Use of topoisomerase 2 alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy.
Authors
S. Chan
Nottingham University Hospital, Nottingham, United Kingdom
S. Chan , J. S. Reis-Filho , P. D. Dickinson , P. Moseley , A. R. Green , I. O. Ellis , T. M. A. Abdel-Fatah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1027)
Abstract #
1027
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2011 Breast Cancer Symposium
Effect of oral cyclophosphamide use on pathologic complete response rate in the neoadjuvant treatment of breast cancer.
First Author: M. Luque
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2023 ASCO Annual Meeting
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
First Author: Rebecca Arielle Shatsky